

In the Specification:

Please amend the paragraph at page 1, lines 12-14, as follows:

This application is a national phase application, filed under 35 U.S.C. 1.371, of PCT/US03/040701, which claims priority of U.S. Provisional Application Serial No. 60/434,918, filed 20 December 2002, and 60/463,577, filed 17 April 2003, the disclosures of which are hereby incorporated by reference in their entirety.

Please amend the paragraph at page 8, lines 6-11, as follows:

The the term "nucleotide sequence" refers to a heteropolymer of deoxyribonucleotides. Generally, DNA segments encoding the proteins provided by this invention are assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon.

Please amend the paragraph at page 14, lines 6-9, as follows:

Combining data from the genomic DNA analysis of gains in the tumor cell lines/clinical samples with mRNA expression analysis from the same and matched tumor types displayed on an assembled human genome ~~sequence~~ sequence obtained from the NCBI Genbank ~~sequence~~ sequence repository.:

Please amend the paragraph at page 14, lines 11-12, as follows:

Regions of genomic amplification were identified in tumor cell lines and clinical tumor samples using ~~comparitive~~ comparative genomic hybridization.

Please amend the paragraph at page 15, lines 4-6, as follows:

The ~~gene~~ genes that were ~~consistently~~ consistently amplified at the genomic level and overexpressed at the mRNA level are further characterized for function (i.e by protein expression, RNA interference).